EP1105150A1 - Traitement de tumeurs au moyen d'oligonucleotides agissant sur le recepteur du facteur de croissance insulunoide i - Google Patents

Traitement de tumeurs au moyen d'oligonucleotides agissant sur le recepteur du facteur de croissance insulunoide i

Info

Publication number
EP1105150A1
EP1105150A1 EP99941078A EP99941078A EP1105150A1 EP 1105150 A1 EP1105150 A1 EP 1105150A1 EP 99941078 A EP99941078 A EP 99941078A EP 99941078 A EP99941078 A EP 99941078A EP 1105150 A1 EP1105150 A1 EP 1105150A1
Authority
EP
European Patent Office
Prior art keywords
tumor
cells
igf
cell
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99941078A
Other languages
German (de)
English (en)
Inventor
David W. Andrews
Renato L. Baserga
Mariana Resnicoff
David Abraham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EP1105150A1 publication Critical patent/EP1105150A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Definitions

  • Tumor cell lines include, but are not limited to, C6 rat glioblastoma cell line, FO-1 human melanoma cell line, B A 1112 rat rhabdomyosarcoma cell line, B 1792-F 10 mouse melanoma, B 16 mouse melanoma, and CaOV-3 human ovarian carcinoma.
  • Tumorous tissue, tumors, or tumor cells can also be excised from the human patient in which the diffusion chamber will be inserted or from another source which has been cultured in vitro.
  • MHC class I associated peptides include, for example, Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala (SEQ ID NO: 10) recognized by melanoma-specific CTL lines (Cox, etal, Science, 1994, 264, 716- 719), Leu-Leu- Asp-Gly-Thr-Ala-Thr-Leu-Arg-Leu (SEQ ID NO: 11) derived from gp 100 and involved in regression of human melanoma (Kawakami, et al, Proc. Natl. Acad. Sci.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé permettant d'induire une résistance à la croissance tumorale ou une régression de la croissance tumorale. Ce procédé consiste à prendre des cellules tumorales et à les mettre en culture in vitro ou ex vivo avec en supplément un agent proapoptotique pendant un certain temps. Le procédé consiste ensuite à transférer ces cellules tumorales dans une chambre de diffusion, produisant ainsi une chambre contenant les cellules. Le procédé consiste enfin à introduire chez l'homme cette chambre pendant une période de traitement suffisante, ce qui induit une résistance à la croissance tumorale ou une régression de la croissance tumorale.
EP99941078A 1998-08-13 1999-08-13 Traitement de tumeurs au moyen d'oligonucleotides agissant sur le recepteur du facteur de croissance insulunoide i Withdrawn EP1105150A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9635498P 1998-08-13 1998-08-13
US96354P 1998-08-13
US11359998P 1998-12-24 1998-12-24
US113599P 1998-12-24
PCT/US1999/018306 WO2000009145A1 (fr) 1998-08-13 1999-08-13 Traitement de tumeurs au moyen d'oligonucleotides agissant sur le recepteur du facteur de croissance insulunoide i

Publications (1)

Publication Number Publication Date
EP1105150A1 true EP1105150A1 (fr) 2001-06-13

Family

ID=26791616

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99941078A Withdrawn EP1105150A1 (fr) 1998-08-13 1999-08-13 Traitement de tumeurs au moyen d'oligonucleotides agissant sur le recepteur du facteur de croissance insulunoide i

Country Status (5)

Country Link
EP (1) EP1105150A1 (fr)
JP (1) JP2002522506A (fr)
AU (1) AU5479899A (fr)
CA (1) CA2339858A1 (fr)
WO (1) WO2000009145A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
MX2017012982A (es) 2015-04-10 2018-07-06 Univ Jefferson Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
EP4378531A2 (fr) * 2017-03-09 2024-06-05 Thomas Jefferson University Méthodes et compositions pour le traitement de cancers à l'aide d'anti-sens
EP3612162A4 (fr) * 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. Acides nucléiques p-éthoxy destinés à inhiber l'igf-1r

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714170A (en) * 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
JP2000500654A (ja) * 1995-11-14 2000-01-25 トーマス・ジェファーソン・ユニバーシティ 可溶性ｉｇｆ−１受容体による腫瘍成長に対する誘導耐性
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
WO1999023259A1 (fr) * 1997-11-04 1999-05-14 Inex Pharmaceutical Corporation Composes antisens du recepteur du facteur de croissance de substances apparentees a l'insuline 1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0009145A1 *

Also Published As

Publication number Publication date
WO2000009145A1 (fr) 2000-02-24
JP2002522506A (ja) 2002-07-23
CA2339858A1 (fr) 2000-02-24
AU5479899A (en) 2000-03-06

Similar Documents

Publication Publication Date Title
Bennett et al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.
US7235534B2 (en) Antisense strategy to modulate estrogen receptor response (ER α and/or ER β )
EP1729788B1 (fr) Traitement de la restenose a l'aide de cellules souches mesenchymateuses
CN107106564A (zh) 用于治疗与kras突变相关的恶性肿瘤的方法和组合物
US20050255510A1 (en) Fra-1 expression in brain cancer
US20200197432A1 (en) Methods And Compositions For Controlling Cardiac Fibrosis And Remodeling
US6506415B2 (en) Method of inducing resistance to tumor growth
US6541036B1 (en) Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
JP2001504487A (ja) インスリン様生長因子１型受容体（ｉｇｆ―１ｒ）アンチセンスオリゴヌクレオチド処理乳癌細胞組成物
WO2011031299A1 (fr) Injections intrapéricardiques
EP1105150A1 (fr) Traitement de tumeurs au moyen d'oligonucleotides agissant sur le recepteur du facteur de croissance insulunoide i
CA2660661A1 (fr) Cellules de population laterale intervenant dans la reparation cardiaque
CN106456771A (zh) 用于抗lyst免疫调节的组合物和方法
WO2009052211A1 (fr) Compositions et procédés permettant d'améliorer la lymphangiogenèse
CN115381949A (zh) 靶向抑制色素上皮衍生因子在促进肝脏再生及改善肝损伤中的应用
JP4170421B2 (ja) 増殖性臓器疾患治療・改善剤
KR20110132908A (ko) Ｔｌｅ1 억제제를 유효성분으로 함유하는 활액막 육종 예방 및 치료용 약학적 조성물
CN115997122A (zh) 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物
Zhang et al. Rac1+ cells distributed in accordance with CD 133+ cells in glioblastomas and the elevated invasiveness of CD 133+ glioma cells with higher Rac1 activity
CN112057471B (zh) 间充质干细胞的制药用途
JP2003527096A (ja) Ｃ−ｍｙｃアンチセンス処理した造血幹細胞組成物および方法
WO1999055382A1 (fr) Vecteur adenoviral codant pour un gene bcl-2 anti-apoptotique et utilisation de ce vecteur
CN117323334A (zh) Nhe1抑制剂在制备防治多发性骨髓瘤的药物中的应用
Frankel et al. Antisense oligonucleotide—induced inhibition of adrenocorticotropic hormone release from cultured human corticotrophs
US20050163761A1 (en) Agent for inducing or inhibiting an angiogenesis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010306

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ABRAHAM, DAVID

Inventor name: RESNICOFF, MARIANA

Inventor name: BASERGA, RENATO, L.

Inventor name: ANDREWS, DAVID, W.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030303